NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 231 filers reported holding NEVRO CORP in Q4 2020. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $791,864 | -24.4% | 41,200 | 0.0% | 0.00% | – |
| Q2 2023 | $1,047,304 | -29.7% | 41,200 | 0.0% | 0.00% | -100.0% |
| Q1 2023 | $1,489,380 | -9.2% | 41,200 | -0.5% | 0.00% | 0.0% |
| Q4 2022 | $1,639,876 | -22.3% | 41,411 | -8.6% | 0.00% | 0.0% |
| Q3 2022 | $2,111,000 | +6.3% | 45,300 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $1,985,000 | -39.8% | 45,300 | -0.6% | 0.00% | 0.0% |
| Q1 2022 | $3,296,000 | -10.0% | 45,574 | +0.8% | 0.00% | 0.0% |
| Q4 2021 | $3,664,000 | -30.3% | 45,200 | 0.0% | 0.00% | -50.0% |
| Q3 2021 | $5,260,000 | -54.1% | 45,200 | -34.6% | 0.00% | -60.0% |
| Q2 2021 | $11,460,000 | +16.5% | 69,121 | -2.0% | 0.01% | +25.0% |
| Q1 2021 | $9,838,000 | -22.6% | 70,521 | -3.9% | 0.00% | -33.3% |
| Q4 2020 | $12,709,000 | +24.3% | 73,421 | 0.0% | 0.01% | 0.0% |
| Q3 2020 | $10,228,000 | +0.9% | 73,421 | -13.5% | 0.01% | 0.0% |
| Q2 2020 | $10,141,000 | +52.6% | 84,880 | +27.7% | 0.01% | +20.0% |
| Q1 2020 | $6,646,000 | +29.4% | 66,470 | +52.1% | 0.01% | +66.7% |
| Q4 2019 | $5,136,000 | +42.9% | 43,700 | +4.5% | 0.00% | +50.0% |
| Q3 2019 | $3,594,000 | +32.6% | 41,800 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $2,710,000 | -59.6% | 41,800 | -61.0% | 0.00% | -50.0% |
| Q1 2019 | $6,707,000 | +33.4% | 107,300 | -17.0% | 0.00% | 0.0% |
| Q4 2018 | $5,028,000 | -55.6% | 129,300 | -35.0% | 0.00% | -42.9% |
| Q3 2018 | $11,333,000 | -89.2% | 198,827 | -84.9% | 0.01% | -90.4% |
| Q2 2018 | $105,130,000 | -20.3% | 1,316,588 | -13.5% | 0.07% | -23.2% |
| Q1 2018 | $131,916,000 | +26.0% | 1,522,048 | +0.4% | 0.10% | +26.7% |
| Q4 2017 | $104,685,000 | -21.8% | 1,516,300 | +2.9% | 0.08% | -25.0% |
| Q3 2017 | $133,910,000 | +44.0% | 1,473,477 | +17.9% | 0.10% | +38.9% |
| Q2 2017 | $93,002,000 | -18.8% | 1,249,524 | +2.2% | 0.07% | -20.9% |
| Q1 2017 | $114,537,000 | +17.4% | 1,222,381 | -9.0% | 0.09% | +12.3% |
| Q4 2016 | $97,595,000 | -30.8% | 1,343,179 | -0.5% | 0.08% | -31.9% |
| Q3 2016 | $140,960,000 | +13.0% | 1,350,324 | -20.2% | 0.12% | +11.2% |
| Q2 2016 | $124,770,000 | +22.1% | 1,691,564 | -6.9% | 0.11% | +23.0% |
| Q1 2016 | $102,203,000 | -22.0% | 1,816,620 | -6.4% | 0.09% | -21.6% |
| Q4 2015 | $131,011,000 | +22.9% | 1,940,615 | -15.5% | 0.11% | +22.0% |
| Q3 2015 | $106,580,000 | +49.7% | 2,297,483 | +73.4% | 0.09% | +54.2% |
| Q2 2015 | $71,201,000 | +255.6% | 1,324,674 | +217.1% | 0.06% | +268.8% |
| Q1 2015 | $20,025,000 | +34.5% | 417,806 | +8.5% | 0.02% | +33.3% |
| Q4 2014 | $14,894,000 | – | 385,168 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tiger Eye Capital LLC | 239,122 | $41,392,000 | 8.25% |
| Integral Health Asset Management, LLC | 88,000 | $15,233,000 | 4.53% |
| Iron Triangle Partners LP | 168,761 | $29,213,000 | 3.79% |
| Eos Focused Equity Management, L.P. | 14,002 | $2,424,000 | 2.37% |
| PFM Health Sciences, LP | 311,940 | $53,997,000 | 1.90% |
| Perceptive Advisors | 977,565 | $169,217,000 | 1.82% |
| Rock Springs Capital Management LP | 395,000 | $68,375,000 | 1.45% |
| Lisanti Capital Growth, LLC | 54,302 | $9,400,000 | 1.30% |
| HealthCor Management, L.P. | 156,046 | $27,012,000 | 1.04% |
| FRED ALGER MANAGEMENT, LLC | 2,136,612 | $369,848,000 | 0.96% |